Stockscreener 앱 받기
34.73
1.86%
-0.66
전일 마감가:
$35.39
열려 있는:
$35.39
하루 거래량:
2.39M
Relative Volume:
1.67
시가총액:
$3.65B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
27.56
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-7.39%
1개월 성능:
-57.19%
6개월 성능:
-52.33%
1년 성능:
-36.20%
1일 변동 폭
$34.54
$35.85
1주일 범위
$34.54
$38.11
52주 변동 폭
$32.99
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
34.73 | 3.72B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Market Overview: Should you avoid Corcept Therapeutics Incorporated stock right nowWeekly Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Rally Mode: Will Corcept Therapeutics Incorporated stock hit new highs in YEAR2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire Inc.
Zacks Research Has Negative Forecast for CORT Q3 Earnings - MarketBeat
Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? - Finviz
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Corcept Therapeutics (NASDAQ:CORT) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Nasdaq Composite Mechanism Strategy - Kalkine Media
Corcept Therapeutics Under Investigation After FDA Response, Shares Plunge Over 50% - Intellectia AI
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Corcept Therapeutics Faces Investigation After FDA Response Letter, Shares Plunge Over 50% - Intellectia AI
Corcept Therapeutics Incorporated Investigated on Behalf of InvestorsContact the DJS Law Group to Discuss Your Rights – CORT - marketscreener.com
INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC - GlobeNewswire
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - PR Newswire
Corcept Therapeutics (BIT:1CORT) Price Target Decreased by 24.29% to 80.62 - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - GlobeNewswire Inc.
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Inflation Data: Why is Corcept Therapeutics Incorporated stock going upJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT) - marketscreener.com
Bank Watch: Why is Corcept Therapeutics Incorporated stock going upWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors ... - Bluefield Daily Telegraph
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated - GlobeNewswire
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day - Yahoo Finance
Why Corcept (CORT) stock is trading lower today - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect - ACCESS Newswire
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook - MSN
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) - Business Wire
Will Corcept Therapeutics Incorporated (HTD) stock outperform benchmarksWeekly Market Outlook & AI Powered Buy/Sell Recommendations - ulpravda.ru
Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter - Finviz
Is Corcept Therapeutics Incorporated stock positioned for long term growthJuly 2025 Rallies & Capital Protection Trading Alerts - ulpravda.ru
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Corcept Therapeutics (CORT): Analyst says shares pricing in growth, new launch - MSN
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 20,000 Shares of Stock - MarketBeat
Guyer, Corcept therapeutics officer, sells $703k in shares By Investing.com - Investing.com Canada
CORT ALERT: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated for Possible Securities Fraud Violations - ACCESS Newswire
Is Corcept Therapeutics Incorporated stock in correction or buying zoneDip Buying & High Accuracy Investment Signals - ulpravda.ru
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics ... - Bluefield Daily Telegraph
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Why Corcept Therapeutics Incorporated stock is a must watch in 2025 - ulpravda.ru
Published on: 2026-01-08 22:12:30 - ulpravda.ru
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
Why is CORT stock falling today? - MSN
Relacorilant for Cushing’s disease - Cushing's Disease News
Corcept Therapeutics Shares Plunge Over 50% Following FDA Complete Response Letter - Intellectia AI
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Buybacks Report: Is Corcept Therapeutics Incorporated HTD stock among top earnings playsJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT) - TMX Newsfile
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):